勵晶太平洋：2024中期報告.pdf

1、2Performance Overview業績概覽4Managements Discussion and Analysis of the Groups Performance管理層對本集團業績之 討論及分析14Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income簡明綜合損益及 其他全面收益表16Condensed Consolidated Statement of Financial Position簡明綜合財務狀況表18Condensed Consolidated Statement

2、 of Changes in Equity簡明綜合權益變動表19Condensed Consolidated Statement of Cash Flows簡明綜合現金流量表21Notes to the Condensed Consolidated Financial Statements簡明綜合財務報表附註60Trading Record Over Last Five Years過去五年營業紀錄61Other Information其他資料73Definitions釋義80Corporate Information公司資料CONTENTS目 錄2REGENT PACIFIC GROUP LI

3、MITED 勵晶太平洋集團有限公司PERFORMANCE OVERVIEW業績概覽 截至二零二四年六月三十日止六個月之財務業績概要及其他重要事件包括：本公司股東應佔虧損約2,620,000美元，主要是由於本集團的營運及研發開支約2,610,000美元。截至二零二四年六月三十日，本集團錄得資本虧損約4,070,000美元，增加主要源自本公司股東應佔虧損。Senstend於中國的進展方面，江蘇萬邦醫藥的主要目標仍為於二零二四年底前向國家藥品監督管理局提交新藥申請，預期將於12個月後獲得批准。倘國家藥品監督管理局授予Senstend進口許可證，江蘇萬邦醫藥將須向本集團支付5,000,000美元（扣除

4、中國預扣稅前）。此外，Senstend於中國進行首次商業銷售後，江蘇萬邦醫藥將須向本集團支付2,000,000美元（扣除中國預扣稅前）。Fortacin於美國的進展方面，本公司正在評估兩家知名臨床研究機構關於在美國開展第三期臨床研究的方案。Recordati繼續獲得Fortacin的不間斷供應，該產品的主要市場為意大利及德國。其他地區（即東南亞若干國家）方面，我們的被許可方正繼續與新製造商商討條款，包括(i)向有關衞生當局提交變更以委任新製造商的監管支援；及(ii)在其各自地區製造及供應Fortacin的商業條款。A summary of the financial performance a

5、nd other notable events for the six months ended 30 June 2024 include:A loss attributable to shareholders of the Company of approximately US$2.62 million,which was mainly attributable to the Groups operating and R&D expenses of approximately US$2.61 million.The Group recorded a capital deficiency of

6、 approximately US$4.07 million as at 30 June 2024,with the increase being mainly due to the loss attributable to shareholders of the Company.In respect of the progress being made with Senstend in the PRC,the main objective remains for Wanbang Biopharmaceutical to submit the NDA to NMPA by the end of